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Abstract
Background: Mounting clinical and experimental evidence suggests that the shift of carcinomas towards a mesenchymal
phenotype is a common paradigm for both resistance to therapy and tumor recurrence. However, the mesenchymalization
of carcinomas has not yet entered clinical practice as a crucial diagnostic paradigm.
Methodology/Principal Findings: By integrating in silico and in vitro studies with our epithelial and mesenchymal tumor
models, we compare herein crucial molecular pathways of previously described carcinoma-derived mesenchymal tumor
cells (A17) with that of both carcinomas and other mesenchymal phenotypes, such as mesenchymal stem cells (MSCs),
breast stroma, and various types of sarcomas. We identified three mesenchymal/stromal-signatures which A17 cells shares
with MSCs and breast stroma. By using a recently developed computational approach with publicly available microarray
data, we show that these signatures: 1) significantly relates to basal-like breast cancer subtypes; 2) significantly relates to
bone metastasis; 3) are up-regulated after hormonal treatment; 4) predict resistance to neoadjuvant therapies.
Conclusions/Significance: Our results demonstrate that mesenchymalization is an intrinsic property of the most aggressive
tumors and it relates to therapy resistance as well as bone metastasis.
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Introduction
Despite progress in both knowledge and treatment, breast
cancer remains the major cause of morbidity and mortality in
Western Countries [1]. Mounting clinical and experimental
evidence suggests that the shift of carcinomas towards a
mesenchymal phenotype is a common paradigm of both resistance
to therapy and tumor recurrence. Pharmacological and radio-
therapeutic treatments induce the acquisition of mesenchymal
features and increased cell motility [2–7]. In HER-2/neu
experimental tumors, the anti-apoptotic mutations induce an
aberrant evolution of the stroma [8]. The spontaneous develop-
ment of mesenchymal tumors after epithelial cell regression has
been proposed as a model of tumor recurrence [9]. This evidence
demonstrates that the capacity to generate mesenchymal tumor
cells is inherent in carcinomas, and suggests they could
spontaneously evolve into mesenchymal tumors if the epithelium
is attacked.
Despite increasing awareness of the contribution of mesenchy-
mal-like cells to cancer progression, the real incidence of
mesenchymalization in human carcinomas still remains elusive
and has not yet entered clinical practice as a crucial diagnostic
paradigm. Furthermore, in the past few years, emerging evidence
that mesenchymal stem cells (MSCs) may support [10–12] and
generate tumors [13–16], as well as the recent discovery that
cancer stem cells exhibit a mesenchymal phenotype [17], suggests
that carcinoma mesenchymalization is a multi-faced phenomenon
which may also proceed in ways alternative to epithelial-to-
mesenchymal transition. Taken as a whole, these findings highlight
the importance of relating the occurrence of this phenomenon to
disease outcome in clinic settings.
From a mammary carcinoma spontaneously developed in
HER-2/neu transgenic mice, we previously established a carci-
noma derived mesenchymal tumor cell lineage, called A17 [18],
capable of developing highly aggressive mesenchymal tumors
when injected into syngeneic mice. Here, we describe three
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e14131mesenchymal/stromal-signatures which A17 cells share with
mesenchymal stem cells (MSCs) and breast stroma, and show
that these signatures: 1) significantly relates to basal-like breast
cancer subtypes; 2) significantly relates to bone metastasis; 2) are
up-regulated after hormonal treatment; 3) predict resistance to
neoadjuvant therapies.
Results
CaMTCs exhibit different signaling pathways compared
to epithelial cells
First, we characterized A17 cells for the expression and
activation state of the MAP kinase ERK1/2, p-38, and the Ser/
Thr Kinase Akt, which are known to be key molecules in cancer
cell signaling pathways. Interestingly, we found that A17 cells
exhibited a distinctive pattern of expression and activation of these
molecules with respect to syngeneic epithelial cancer cells (BB1
and sB7) (Figure 1a).
We previously showed that A17 exhibited a stemness-related
gene signature which was virtually identical to that of MSCs and
an angiogeneic-related signature which had significantly higher
correlation to that of MSCs with respect to that of syngeneic breast
cancer cells (BB1) [10]. Herein our comparative analysis of A17s,
MSCs and BB1s was extended to include a set of 96 genes involved
in the most important cancer signaling pathways (Table S1). In
accordance with previously described transcriptional analysis, A17
cells proved to be more highly related to MSCs than to epithelial
lineages (BB1 cells and tumors, sB7 cells, Spontaneous tumors) also
for signal transduction-related genes (Figure 1b and Table S2).
However, A17 tumors proved to be more closely correlated to the
epithelial tumor profile (BB1 and Spontaneous tumors) than to
that of mesenchymal or epithelial cells.
Several cancer genes showed different expressions in A17 cells
with respect to syngeneic epithelial cells (BB1 and sB7). Differences
in angiogenesis-related genes have been shown previously [10].
Among the cancer signal transduction pathway-related genes
(Table S1), dual specificity phosphatase 1 (Dusp1) and COX-2 (also
known as PTGS2) were significantly over-expressed (2.34-fold, Q
value=0.008 and 3.77-fold, Q value=0.029, respectively) in the
mesenchymal profile (A17 cells, A17 tumors, MSCs) with respect
to all the epithelial lineages.
COX-2 is a mesenchymal hallmark in tumors
The importance of COX-2 in growth, vasculogenesis and
invasiveness has been widely documented in various types of
carcinoma, both in clinical and experimental studies. However, our
microarray analysis suggests that COX-2 is a key molecule in the
malignant phenotype of mesenchymal tumor cells. In order to
investigate this hypothesis, the expression and functional activity of
COX-2 were further investigated. We confirmed at transcriptional
and protein level the overexpression of COX-2 in A17 compared to
syngeneic epithelial lineages (Figure 1c–e). Furthermore, we also
observed that COX-2/PTGS2 expressed by A17 was enzymatically
active, as it was phosphorylated (Figure 2a) and the PGE2
production by A17 cells proved to be sensitive to both non-selective
(Indometacin) and selective (NS-398 and Tyrphostin) COX-2/
PTGS2 inhibitors (Figure 2b). Moreover, we observed that the
differential expression of COX-2/PTGS2 between A17 and BB1
cells was epigenetically regulated(Figure S1). Finally we found that
COX-2/PTGS-2 was implicated in promoting cell motility and
invasiveness of A17, given that its blocking by means of selective or
non-selective inhibitors significantly hampered A17 migration
through Matrigel and motility in vitro (Figure 2e and f).
Afterward, we were interested in mapping COX-2 expression in
human tumors. To this end, we analyzed COX-2 expression values
in a cohort of 2789 microarray datasets of human breast stroma,
MSCs, and varied tumor histotypes, collected from publicly
available databases (Figure 2g and Table S3). In order to
minimize false discovery due to normalization errors, we cross-
validated the data by two complementary approaches. First, we
calculated the percentage fraction of samples expressing COX-2
values higher than three times the whole-genome intra-sample
median value. This approach is not affected by the inter-sample
noise due to normalization error and captures information about
whether COX-2 is both a highly expressed gene within the
transcriptome of a given sample. Secondly, we calculated the
percentage fraction of samples where COX-2 expression values
were higher than three times the COX-2 median value across all
samples of the dataset. Both approaches demonstrated that stroma
samples expressed the highest values of COX-2, closely followed by
MSCs and then bladder and prostate cancers, demonstrating that
COX-2/PTGS2 is a hallmark of the mesenchymal phenotype
(Figure 2h and Table S4). Gastrointestinal stromal tumors
exhibited very high COX-2 levels using the first approach, but it
was not confirmed in the second one
A17 stemness-, angiogenesis- and signal transduction-
signatures are over-represented in MSCs and Breast
Stroma
We were interested in systematically relating carcinoma-derived
mesenchymal tumor cells to varied human breast cancer histotypes
and their potentialclinical outcome. To this end, we took advantage
of a recently developed computational algorithm, named GENO-
MICA [19], which makes it possible to quantify and statistically
evaluate the enrichment of one or more gene sets in all samples of a
given microarray dataset compendium (Figure 3a). Specifically, it
tests whether the fraction of over- or under-expressed genes in each
profiled sample includes a higher than randomly expected fraction
of genes from one or more gene sets under analysis. Cut-offs for
over- and under-expression are established by the user as a
parameter of the analysis. A second step in the analysis assesses
whether particular sample groups (experiment sets such as MSCs or
Basal-like tumors, etc.) preferentially over- or under-express
particular gene sets. In both steps, statistical evaluation of the
enrichment is inherent in the computational algorithm. It calculates
the p value of the fraction of over- or under-expressed genes
according to hypergeometric distribution.
First, we compiled 3 gene sets, thereafter referred to ‘‘A17
signatures’’, (Table S5) as follows: 1) A17-stemness signature:
comprised genes of a stemness-related gene microarray the
expression of which in A17 cells was higher or equal to the
intra-sample median value; 2) A17-angiogenesis signature:
comprised genes of an angiogenesis-related gene microarray the
expression of which in A17 cells was higher or equal to the intra-
sample median value; 3) A17-signal transduction signature:
comprised genes of a cancer signal transduction-related gene
microarray the expression of which in A17 cells were higher or
equal to the intra-sample median value.
In order to relate the A17 phenotype with that of other
mesenchymal phenotypes involved in tumorigenesis, we analyzed
the enrichment of these A17 Signatures in a compendium of 360
publicly available human whole-genome microarray datasets,
including samples of MSCs, breast stroma, breast cancer and
varied types of sarcoma (Figure 3b).
After concatenating datasets, we normalized the entire com-
pendium with the Robust Multiarray Average (RMA)-algorithm.
The dataset samples included in the compendium were grouped
Cancer Mesenchymalization
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whole-genome microarray datasets of breast tumors; 2) Normal
Breast: comprised whole-genome microarray datasets of normal
tissue from invasive ductal or lobular breast carcinomas. 3) Breast
Stroma: comprised whole-genome microarray datasets of stroma
samples from normal or tumor breasts; 4) Breast Organelle:
comprised whole-genome microarray datasets of breast organelles;
5) MSCs: comprised whole-genome microarray datasets of MSCs;
6) Sarcomas: comprised whole-genome microarray datasets of
varied types of sarcomas.
All three gene sets were significantly over-represented in MSCs
and breast stroma and significantly under-represented in breast
cancers (Figure 3c). Sarcomas did not exhibit significant over-
expression or under-expression of any of A17-signatures. Accord-
ingly, breast stroma samples, MSCs and breast organelle expressed
the highest values of COX-2 (Figure 3d). However, both A17-
signatures and COX-2 were heterogeneously expressed in breast
cancers, indicating subsets of breast cancer that over-express a
mesenchymal related phenotype.
A17-signatures identify ER-negative breast cancers
In order to systematically relate breast cancer mesenchymaliza-
tion to any clincopathologic parameters, we analyzed the A17-
signature expression using two publicly available microarray
Figure 1. Signal transduction-related profile of A17. A17 cells exhibit a clearly different pattern of expression and activation (phosphorylation)
of key signal transduction molecules compared to syngeneic epithelial cell lines (BB1 and sB7) (a). ERK1/2 or Akt proved to be constitutively
expressed but not phosphorylated in A17 cells. In contrast, P-ERK1/2 and P-Akt were found in both BB1 and sB7 cells, where they are presumably
recruited downstream of the HER-2/neu signaling pathway. Furthermore, whereas both epithelial and A17 cells proved to express Focal Adhesion
Kinase (FAK), we found an increased phosphorylation of paxillin and p130 Cas in A17 cells, which is in line with the constitutively motile phenotype of
these mesenchymal cells. p-38 was expressed and activated in both epithelial and A17 cells. Microarray analysis restricted to 96 signal transduction-
related genes show the A17 cell profile to be more related to that of MSCs than that of syngenic epithelial cells (BB1). However, the A17 tumor profile
was shown to be more correlated to that of epithelial tumors than that of epithelial or mesenchymal cells (b). The differential expression of COX-2 in
A17 compared to epithelial cells was confirmed at the transcriptional level through quantitative real-time PCR (Figure 1c). Western Blot analysis
confirmed the differential expression of COX-2, but not of COX-1, in A17 cells and tumors comapared to BB1 cells and tumors (figure 1d). Differential
expression of COX-2 protein between A17 and BB1 was also confirmed by immunocytochemistry on cell cultures (Figure 1d, right-up panles) and
immunohistochemistry on tumor slices (figure 1e).
doi:10.1371/journal.pone.0014131.g001
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PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e14131Figure 2. COX-2 was enzimatically active in A17 cells and regulated motile phenotype. Expression of the active (phosphorylated) isoform
of COX-2/PTGS2 was confirmed by western blotting in not-treated A17 cells (a). PGE2 production (b) was assessed on A17 cells treated with
Arachidonic Acid (control condition), preincubated with indomethacin (10 mM), NS-398 (10 mM and 100 mM) or Tyrphostin 47 (300 mM) for
30 minutes. Bars represent mean 6 SD of three independent experiments with triplicate samples. ##p,0.01; # p,0.05 in a standard Student t-
test. A17, but not BB1, exhibited an efficient motility throughout the Boyden chamber (c). Blocking COX-2/Ptgs2 with both selective (Indometacin)
and not-selective (NS-398) inhibitors significantly reduced the motility of A17 cells in Boyden chamber assay (d) as well as A17 invasivity in matrigel
(e). Bars represent mean 6 SEM of three independent experiments with triplicate samples. * p,0.01 in a standard Student t-test. Treatment with
Cancer Mesenchymalization
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human patients. The former [20] comprised 295 human breast
cancers with mixed ER, grade and lymph node status, the latter
[21] comprised 286 human breast cancers, which were all lymph
node negative.
In Van de Vijver’s cohort (figure 4a), A17-stemness and signal
transduction-signature were significantly enriched in ER-negative
tumors, and the A17-stemness signature relates to the death of the
patient. In Wang’s cohort (Figure 4b), the A17-stemness
signature was confirmed to be enriched in ER-negative tumors,
but was inversely related to relapse events, suggesting a lower
prognostic value of this signature in lymph node negative tumors.
The A17-signal transduction signature was not significantly
enriched in ER-negative tumors. On the contrary, the A17-
angiogenesis signature was over-expressed in ER-negative tumors
and was related to brain relapse. These data suggested that A17-
signatures were enriched in ER-tumors, with some differences
related to the lymph node status.
A17-signatures relate to basal-like breast tumors
Based on the most differentially expressed genes, Sorlie et al.
[22] previously identified five ‘intrinsic subtypes’ of breast cancer,
strongly related to different clinical outcomes: normal-like, luminal
type A, luminal type B, HER-2-like and basal-like. Tumors
referred to as basal-like, or triple-negative tumors, exhibit the
worst prognosis and are recognized by the combination of ER-/
PR-/HER-2- negativity and KRT5-/KRT14-/FOXC1-/FABP4-
positivity. In accordance with that method, unsupervised cluster-
ization of Van de Vijver’s dataset filtered by a standard deviation
of $0.4 allowed us to identify the same five breast cancer subtypes
described by Sorlie et al. As expected, the basal-like tumors
showed a higher frequency of patient death, reduced time
recurrence and survival (Figure 4c, yellow frame).
Module map analysis of the Van de Vijver’s cohort showed that
basal-like tumors were significantly enriched in all three A17-
signature (Figure 4d).
A17-signatures are over-expressed in bone metastasis
compared to brain or lung metastasis
Cancer cells need to acquire a mesenchymal phenotype to
disseminate and form metastasis, but it is commonly thought that
metastatic cells revert to an epithelial phenotype after reaching a
permissivedistant site. However, as the most aggressive breastcancers
may stably exhibit a mesenchymal phenotype, it is conceivable that
distant metastasis might also relate to the mesenchymal phenotype. In
order to interrogate this hypothesis, we analyzed the A17-signature
enrichment in a restricted cohort of 29 human distant metastases
(Arrayexpress, accession number E-GEOD-14017) disseminated
from primary breast cancers to lung, brain or bone. Interestingly
we found that all three A17-signatures were significantly over-
expressed in bone metastasis, but significantly under-expressed in
brain metastasis (Figure 5a). Lung metastasis did not exhibit
significant over- or under-expression for these signatures.
A17-signatures are over-expressed after hormonal
therapy
ER-positive tumors, with or without HER-2 over-expression,
usually undergo hormonal therapy. The most used therapeutic
protocol is based on the use of tamoxifen, but recently alternative
drugs have been developed. Although it is accepted that these
treatments frequently improve clinical outcome, a large percent-
age of tumors are ultimately resistant.
In order to assess whether therapy resistance might underlie the
change of the tumor phenotype toward a mesenchymal/basal
phenotype, we collected a cohort of 93 microarray datasets
comprising murine xenografts of human tumors before and after
hormonal therapies. The cohort was obtained by concatenating
microarray data from five independent studies (Table S6). After
concatenating datasets, the cohort was normalized by the RMA-
algorithm and underwent module map analysis to search for the
over- or under-expression of A17-signatures.
Principally, the cohort included murine xenografts of human
ER-positive breast cancer cells (MCF-7), with or without HER-2
over-expression, supplemented or not with estrogen (E2). A limited
number of samples of human colon carcinoma (COLO-205) or
melanoma cells (SK-MEL5) were also included. Colon carcinoma
and melanoma xenografts underwent PEP008 treatment and some
samples of MCF-7 underwent PEP008-based treatment, but most
of the MCF-7 xenografts were treated with a tamoxifen-based
therapy. We assigned samples to two experiment sets, which were
‘‘before’’ and ‘‘after treatment.’’
As expected, module map analysis showed that A17-signatures
(angiogenesis and signal transduction) were significantly under-
expressed in ‘‘before treatment’’ groups of samples (figure 5b).
This result indicates that post-treatment samples have a higher
expression of A17-signatures compared to pre-treatment samples.
In order to further characterize the phenotypic change induced
by the treatment, we clusterized the expression values of a
restricted gene set including well known mesenchymal, basal-like
and epithelial markers (Figure 5c). Interestingly, we found that
the highest fractional percentages of ‘after-treatment’ samples fell
into two clusters, which were identified by the highest expression
of HER-2 and KRT5, respectively.
A17-signatures predict resistance to neoadjuvant
therapies
Farmer et al [23] recently identified a stroma-related signature
which predicts resistance to neoadjuvant therapies in human
breast cancer, but fails to function as an intrinsic prognostic
marker of clinical outcome. The results shown above demonstrat-
ed that the combination of our A17 signatures are intrinsically
effective in identifying the most aggressive breast tumors (basal-
like) and bone metastasis, in predicting clinical outcome and in
characterizing changes associated to hormonal therapy-resistance
in ER-positive breast tumors. In order to assess whether A17-
signatures might also be effective in predicting resistance to
neoadjuvant therapies, we mapped their enrichment in a cohort of
human samples obtained by concatenating Farmer’s study (102
samples, all ER-negative) with a previous study from the same
laboratory [24] (125 samples, all ER-negative). Both of the two
independent studies included human breast tumors subjected to
neoadjuvant non-taxane regimens with 5-fluorouracil, epirubicin,
and cyclophosphamide (FEC). In accordance with the original
papers, samples were assigned to two types of outcome, which
were complete or not complete pathological responses (pCR and
npCR, respectively). pCR was defined as the disappearance of the
invasive component of the primary tumor after treatment, with at
Indometacin also inhibited A17 cell migration, within 18 h, into the gap after scraping of the confluent sheet (f, I:control; II, indometacin treated).
Representative data from three independent experiments are shown. An in silico analysis on 2789 samples including varied types of human tumors,
MSCs, and breast stroma (g) demonstrated the highest levels of COX-2 expression in breast stroma and MSCs (h and Table S4 online).
doi:10.1371/journal.pone.0014131.g002
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resection specimens.
As the original studies were based on a similar experimental
design, the datasets were normalized as described by Segal et al.
[19]. Briefly, the original datasets were log2 transformed and
normalized separately by subtracting the mean value of the genes
across the samples from each data point. After normalization, the
original datasets were concatenated in an unique dataset.
Interestingly, pCR proved to significantly under-express A17-
stemness and A17-signal transduction signatures, whereas npCR
did not (Figure 6a).
Unsupervised hierarchical cluster analysis of the most differen-
tially expressed genes (SD.1.5; 313 genes passed filter) of the
entire cohort confirmed npCR samples to be enriched in the
subtype with a basal-like phenotype (ER-negative, HER-2-
negative, KRT5-positive) compared to the ER-negative/HER-2-
positive-subtype (Figure 6b). Interestingly, COX-2 were over-
expressed in this basal-like subtype, confirming this molecule as a
marker of basal-like breast tumors.
Basal-like breast tumor subtypes are breast cancers
Our results demonstrate that the most aggressive (basal-like
subtype), or therapy-resistant breast tumors, frequently over-
express mesenchymal/stromal signature. However, that does not
necessarily means they are mesenchymal tumors. Thus, we were
interested in comparing the general expression analysis of all
breast cancer subtypes to that of tumor-related mesenchymal
phenotypes. To this end, we systematically analyzed the above-
described RMA-normalized human cohort (Figure 3a), including
breast cancers, along with MSCs, breast stroma and sarcoma
samples (Figure S2 and S3). Taken as a whole, our analysis
shown that, although significantly enriched for mesenchymal/
stromal genes, basal-like tumors prevalently exhibit an epithelial
signature.
Discussion
Breast cancer is a multi-faced disease where histologically
divergent cell populations interact to carry out aberrant programs
of development. All therapeutic approaches that have been
developed in the last few decades suffer from limited efficacy,
due to the wide heterogeneity of tumors and to their ability to
elude treatment by activating alternative developmental programs.
Discovering biological paradigms that could characterize and
identify the ‘‘heart’’ of the most aggressive tumors beyond their
apparent heterogeneity represents a crucial challenge for diagnos-
ing tumor subtypes, forecasting its potential outcome and
developing appropriate therapies.
Different lines of evidence converged toward the notion that
breast tumors have a mesenchymal ‘‘heart.’’ However, for decades
the major efforts in the fight against breast cancer have searched
for diagnostic parameters and therapeutic targets directly or
indirectly related to the epithelial phenotype, such as HER-2,
estrogen receptors, progesterone receptors, anatomical architec-
ture of the gland, and ductal or luminal morphology. Only in the
last years, the convergence of several studies from different areas of
research has given rise to the notion that mesenchymalization is an
intrinsic potential of breast cancers, and that it can proceed from
alternative mechanisms other than EMT, such as the neoplastic
transformation of mesenchymal or epithelial stem cell precursors
[2–9,11,13–16,25,26].
The key finding of our study is that the shift toward a
mesenchymal/stromal phenotype is an intrinsic property of most
aggressive (basal-like) and therapy-resistant primary tumors, as
well as of bone metastasis. Although our A17 signatures have been
identified in a murine model of mammary cancer, they strongly
related to human MSCs and stromal phenotype and proved to be
unexpectedly effective in identifying basal-like subtypes, bone
metastasis and therapy reistant tumors in humans. This suggest
how mesenchymalization in breast carcinomas may have a cross-
species impact.
A mesenchymal phenotype of basal-like tumors has been
recently shown by Sarrio ` et al [27], which revealed how these
aggressive subtypes of tumors frequently exhibit over-expression of
some EMT markers (vimentin, alpha-SMA, SPARC) and
cadherin switching (down-regulation of E-cadherin and up-
regulation of N-, P- and cadherin-11). We provide herein
additional data in support of this idea, showing that human
basal-like tumors strongly over-express a panel of function-
restricted gene sets (angiogenesis, signal transduction and stem-
ness-related) that are highly specific to carcinoma-derived
mesenchymal tumor cells, but also strongly related to breast
stroma and mesenchymal stem cells (A17-signature).
The fact that unsupervised hierarchical clustering of both
whole-genome and array-set restricted genes didn’t directly
clusterize basal-like tumors with any mesenchymal phenotype
(breast stroma, mesenchymal stem cells, sarcomas) indicates that
basal-like tumors only rarely acquire a completely sarcomatoid
phenotype, whereas the appearance of mesenchymal traits are
more frequently mixed with a variable fraction of epithelial
features. In accordance with this notion, it has been previously
shown that basal-like tumors, more frequently than other breast
Figure 3. A17-signatures are enriched in MSCs and breast stroma. The GENOMICA algorithm makes it possible to quantitatively and
statistically evaluate the enrichment of genes of interest in the samples of a given compendium of microarray datasets (a). Input data consist of the
Dataset compendium and of a collection of Gene sets, the enrichment of which has to be tested. Optionally, samples may be grouped in Experiment
sets. In the example in the Figure, input data comprise a Dataset Compendium with n samples, n Gene Sets and n Experiment sets; Gene set 1
includes genes 1 to 6, whereas Experiment set 2 includes samples 2 to 6, etc. Genes are scored as over- or under-expressed if their values are higher
or lower than given cut off values established by the researcher. GENOMICA analysis consists of statistical evaluation, according to the
Hypergeometric distribution, of whether the fraction of over-expressed (or under-expressed) genes in each sample includes a higher-than-randomly-
expected fraction of genes from a particular gene set. If samples have been grouped in Experiment sets, a second step of analysis assesses whether
specific gene sets are enriched in particular Experiment sets. Output consists of three heat maps: the first (Gene hits) depicts over-expressed (red
squares) or under-expressed (green squares) genes in each sample; the second (beneath the Gene hits) depicts enriched (red squares) or under-
represented (green squares) gene sets in each sample; the third (on the right of Gene Hits) depicts whether particular Gene sets are enriched in
particular Experiment sets. Heat maps report only genes (or Gene sets) which met the criteria of statistical significance in at least 1 sample (or
Experiment set). Black squares indicate genes (or Gene sets) which did not meet the criteria of statistical significance. GENOMICA analysis on a cohort
of 360 publicly available human microarray datasets (b) demonstrated that all three A17 signatures are significantly enriched (red squares) in breast
organelle, breast stroma and MSCs samples, but are significantly under-represented (green squares) in breast cancers (c). Plotting samples along an
increasing order of the COX-2 expression value, it turned out that MSCs and Breast stroma expressed the highest values of COX-2 (d). The upper
histogram displays increasing values of COX-2/PTGS2. The bars beneath depict samples ordered according to their COX-2/PTGS2 expression value.
The different colors indicate the respective sample category each sample belongs to (breast cancer, MSCs, etc.).
doi:10.1371/journal.pone.0014131.g003
Cancer Mesenchymalization
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e14131tumor types, exhibit the presence of restricted spindle cell tumor
areas [28].
Interestingly, despite the fact that the A17-signature was
enriched in ER-negative and even more basal-like primary
tumors, its expression was up-regulated in ER-positive tumors
after hormonal therapy. This suggests that therapeutic treatments
specifically addressed to luminal cancer cells can prompt the shift
toward a mesenchymal, basal-like phenotype. ER-negative tumors
are preferentially subjected to preoperative (neoadjuvant) chemo-
therapy, which leads to the disappearance of the primary tumor
Figure 4. A17-signatures are enriched in basal-like breast tumors. Module map analysis of Van the Vijver’s (a) and Wang’s (b) cohort
indicated that A17-signatures were enriched in ER-negative human breast cancers. ‘Intrinsic subtypes’ of breast cancers with different clinical
outcomes were identified on the Van de Vijver’s cohort based on the clusterization of the most differentially expressed genes (c). Module map
analysis using these subtypes as experimental groups demonstrated that all A17 signatures were significantly enriched in the basal-like subtype (d).
doi:10.1371/journal.pone.0014131.g004
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e14131Figure 5. A17-signatures are enriched in bone metastasis and are up-regulated after hormonal therapy in ER-positive tumors.
Module map analysis of public available microarray dataset of human metastatic tumors disseminated from primary breast cancers demonstrated
that A17-signatures were significantly over-represented in bone metastasis samples and under-expressed in brain metastasis samples (a). Module
map analysis on murine xenotransplats of breast tumor cells before and after hormonal therapy showed that A17-signatures were significantly under-
represented in samples before treatment (b). Hierarchical clusterization for a restricted gene set of epithelial, basal-like and mesenchymal markers (c)
showed that the highest percentages of ‘after treatment’ samples fell in two clusters, which were characterized by the higher-then-median
expression of HER-2 and KRT5, respectively.
doi:10.1371/journal.pone.0014131.g005
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tumors, whereas its efficacy is limited to less than 10% of ER-
positive tumors [29–31]. Farmer et al [23] described a stroma-
related gene signature capable of predicting resistance to
neoadjuvant chemotherapy. However, this stroma-related signa-
ture was not able to capture information about the innate
aggressiveness of the tumor, thus failing to forecast the clinical
outcome of tumors independently of neoadjuvant treatment.
Authors cited a previous study which described a new stroma-
derived prognostic predictor (SDPP) obtained by microdissected
tumor stroma [32]. They explained the different results in the two
studies on the basis of the fact that their signature assessed only a
single aspect of gene expression in the stroma, whereas SDPP was
a composite signature that takes into account multiple cell types
and processes occurring in the stroma. A17-signature proved,
indeed, to be able to identify more aggressive and lethal tumors, as
well as to predict resistance to neoadjuvant therapies in ER-
negative tumors.
The key feature of the A17-signature is that, although strongly
related to breast stroma and MSCs, it derives from carcinoma-
derived mesenchymal tumor cells, thus identifying the neoplastic
counterpart of the mesenchymal phenotype in breast cancers. This
high neoplastic-mesenchymal specificity may explain the prognos-
tic other than predictive efficacy of A17-signature.
The major challenge in the fight against tumors is to eradicate
metastasis in distant sites. Bone is the site of metastatization for up
to 70% of patients with advanced breast cancer [33]. The onset
and growth of a metastatic focus in a distant site is due to intrinsic
features of both the host microenvironment and the disseminating
cancer cell. The most commonly accepted model of carcinoma
metastatization provides that epithelial cells incur in EMT to
actively disseminate from the primary tumor, but then revert
toward an epithelial phenotype after reaching the permissive
distant site. We show herein that bone metastasis retains a
mesenchymal/stromal/basal-like phenotype. It cannot be known
whether this phenotype is due to a selection process by the bone
sites or to an intrinsic property of the disseminating cells capable of
reaching the bones. However, the evidence of the mesenchymal
nature of breast-cancer derived bone metastasis strongly suggests a
new approach to searching for more targeted therapies.
A key feature of our A17-signature is the over-expression of
COX-2. For a long time this molecule has been known to
significantly correlate with poor prognosis in breast cancer.
However, as far as we are aware, nobody has shown that its
expression is restricted to breast stroma and MSCs and can
identify breast cancer mesenchymalization. Our results propose
COX-2 as an additional bio-marker of breast cancer mesenchy-
malization and target for therapy in addressing the most aggressive
tumors, i.e. the basal-like ones.
Methods
Cells and tumors
A17 and BB1 cell lines were established from a mouse
mammary carcinoma model (FVB/neuT transgenic mice) as
previously described [18].
Figure 6. A17 signature under-expression predicts response to neoadjuvant therapy. Module map analysis on a cohort of samples
completely (pCR) or not completely (npCR) sensitive to neoadjuvant therapy demonstrated that A17 signatures are under-expressed in pCR samples
(a). Hierarchical clusterization of the dataset filtered for the most differentially expressed genes (SD.1.5) generated two major clusters, one of which
exhibited features of Basal-like tumors (b: yellow frame). The basal-like cluster included a higher percentage of npCR samples than the other cluster.
doi:10.1371/journal.pone.0014131.g006
Cancer Mesenchymalization
PLoS ONE | www.plosone.org 10 November 2010 | Volume 5 | Issue 11 | e14131Mesenchymal stem cells (MSCs) were isolated from inguinal
adipose tissues of FVB mice and identified on the basis of their
immunophenotypical profile and their in vitro multilineage
plasticity toward adipocytes, chondrocytes and osteocytes, as
previously described
10.
Experimental tumors were induced by s.c. injection of 1610
5
A17 or BB1 cells into the groins of 5–7 weeks-old female FVB/
neuNT233 mice.
Microarray
All the steps of microarray analysis for signal transduction-
related genes were performed using reagents from Superarray
Biosciences Corporation (Friederick, CA, USA), closely following
the manufacturer’s instructions. Briefly, total RNA was isolated
from samples using the Qiagen RNeasy kit (Qiagen). The
TrueLabeling-AMP
TM Linear RNA Amplification Kit (Super-
Array Bioscience Corp. Frederick MD) was used to amplify and
label RNA for hybridization. Labeled cRNAs were hybridized
overnight at 60uC with the arrays. After washing, hybridization
was revealed by Chemioluminescence and the array image was
captured by X-ray film and a flatbed desktop scanner. Data from
arrays was analyzed using GEArray Expression Analysis Suite
(Superarray). Quantitative expression values were corrected to the
background, normalized with respect to the positive control genes
included in the arrays, and reported as ratios to the mean values of
normalization genes. We have deposited the raw data at GEO
database under accession number GSE22663, we can confirm all
details are MIAME compliant.
Phospho-protein purification
10
7 A17 cells were assayed with Phospho-Protein Purification
kit (Qiagen, Milano, Italy) closely following manufacturer’s
instructions, with minor modifications.
Real Time PCR
Quantitative PCR was performed on a Real Time PCR System
(Stratagene, Mx3000P) using the real master mix kit (Eppendorf,
Milano, Italy), containing SYBR Green (1mM dNTPs, 10mM
(CH3COO)2Mg and 0.05U/ml HotMaster Taq polymerase). We
used the following primers (400 nM) to amplify each target gene:
COX-2/Ptgs2 (178 bp): 59-TGCTCACGAAGGAACTCAGC-39
for forward primer and 59-CTCATACATTCCCCACGGTTT-
TG-39 for reverse primer. GAPDH (97 bp), 59-GAAGCTTGT-
CATCAACGGGAAG-39 for forward primer and 59-ACTCCAC-
GACATACTCAGCAC-39 for reverse primer. Reactions were
carried out for 45 cycles following an initial template denaturation
step of 90 s at 94uC. The cycle conditions were: 30 s at 94uC, 30 s
at 57uC and 30 s at 72uC.
Western Immunoblotting
Confluent cells were lysated directly into the 25 cm
2 culture
flasks using a boiling sample buffer without beta-mercaptoethanol
(50 mM Tris pH 6.8, 2% SDS, 10% Glycerol). After electro-
blotting onto polyvinylidene difluoride (PVDF) membranes
(Immobilon P, Millipore, Milano, Italy) antigens were probed as
follows: anti-COX-2/PTGS2 polyclonal rabbit primary antibody
(Cayman, Ann Arbor, MI)(1:1000), anti-COX-1 polyclonal rabbit
primary antibody (Cayman, Ann Arbor, MI) (1:200), Rabbit
(polyclonal) Anti-Human FAK (Biosource International, cat.-
no. AHO0502) (1:200), Anti-paxillin (Transduction Laboratories,
Cat. No. P13520) (1:1000), anti-Phospho-Paxillin (Tyr118) Anti-
body (Cell Signaling technology, Cat. No. 2541) (1:750), anti-Akt
Antibody (Cell Signaling Technology, Cat.no. 9272) (1:500), anti-
Phospho-AKT (Ser473) Antibody (Cell Signaling technology, Cat.
no. 9271) (1:1000), anti-p44/42 MAP Kinase (3A7) Mouse mAb
(Cell Signaling technology, Cat. no. 9107) (1:1000), anti-p44/42
MAP Kinase (Thr202/Tyr204) (E10) Monoclonal Antibody (Cell
Signaling technology, Cat. no. 9106) (1:1000), anti-P38 MAP
Kinase Antibody (Biolabs, Cat. No. 9212) (1:1000); anti-Phosphor-
p38 MAP Kinase (Thr180/Tyr182) Antibody (Biolabs, Cat.-
no. 9211S) (1:1000), anti-b-actin monoclonal primary antibody
(Oncogene, Boston, MA) (1:5000).
Monoclonal antibody (mAb) 1H9 to p130Cas was prepared in
our laboratory, by immunizing mice with a recombinant protein
encompassing amino acids 360–685 of mouse p130Cas cDNA
sequence (a kind gift from Dr S. Hanks, Nashville, USA). 1H9
mAb specificity was tested by using, as a negative control,
fibroblasts derived from p130Cas null mice (a kind gift from Dr H.
Hirai and T. Nakamoto, Tokyo, Japan). 1H9 recognizes p130Cas
by immunoprecipitation and western blotting and its reactivity was
identical to that obtained with the p130Cas mAb from
Transduction Laboratories (BD Biosciences Pharmingen, San
Diego, CA, USA) (unpublished results). Phosphorylation of
p130Cas was detected using the antibody pTyr-PY99 (Santa Cruz
Biotechnology, Santa Cruz, CA).
The immunoreactive bands were detected with ECL detecting
reagents (Amersham Bioscience, Little Chalfont, UK).
For p130 Cas immunodetection, cells were lysated with NP-40
lysis buffer (1% NP-40, 150mM NaCl, 50mM Tris pH 8) and
p130 Cas was immunoprecipitated in G-Sepharose beads before
western immunoblotting.
Immunofluorescence analysis
A17 and BB1 cells grown to confluence on coverslips were fixed
in ice-cold methanol at 220uC for 5 minutes, permeabilized in
PBS containing 0.2% Triton X-100 for 7 minutes and blocked
with PBS–10% BSA for 20 minutes. Cells were then incubated for
1 hour at 37uC with the polyclonal primary antibody against
COX-2/Ptgs2 (Cell Signaling, Danvers, MA) diluted 1:100 in a
blocking buffer and, after washing, with the secondary antibody
Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes, Eugene,
Canada) diluted 1:200. Coverslips were mounted on Mowiol
(Sigma, St. Louis, MO) and the preparations were viewed using a
Leica confocal TCS SP2 microscope.
Immunohistochemistry
Animals were anesthetized with ether and perfused with 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Tumors
were excised from animals and further fixed by immersion in the
same fixative, dehydrated and embedded in paraffin wax.
Paraffin sections of tumors were processed for immunohisto-
chemistry using the avidin-biotin complex (ABC) technique.
Briefly, deparaffinized sections were rehydrated and endogenous
peroxidase activity was quenched by 15-min incubation in a
solution of 3% hydrogen peroxide in methanol. After washing in
0.05 M Tris-HCl buffer (pH 7.6) sections were incubated with the
anti-Ciclooxygenase-2 (1:1000, Cayman Chemical, MI, USA )
overnight. After three washes, sections were then reacted with
biotinylated swine anti-rabbit immunoglobulins (DAKO, Milan,
Italy), diluted 1:400, for 2 hours. The immunoreaction was
detected using a Vectastain Elite ABC kit (Vector, Burlingame,
CA, USA), and then visualized by 3,3 diaminobenzidine
tetrahydrochloride (Dako, Milan, Italy) for 5–10 min. Finally,
sections were dehydrated, coverslipped with Entellan, and
observed in an Olympus BX51 photomicroscope equipped with
a KY-F58 CCD camera (JVC). Control sections were processed as
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was observed in these sections.
COX activity
2610
5 cells were plated onto 24 well plates and grown in DMEM
with 20% FBS for 2–3 days to reach confluency. Cells were washed
twice with PBS and incubated with 30mM arachidonic acid in 1 ml
of DMEM for 10 minutes at 37uC. To investigate the functional
contribution of COX-2/Ptgs2 to total COX activity, cells were
pretreated with the non-selective COX-1 and COX-2/Ptgs2
inhibitor indomethacin (10 mM) (Sigma, St. Louis, MO) or with
COX-2/Ptgs2-selective inhibitor NS-398 (10 mM and 100 mM)
(Sigma, St. Louis, MO) for 30 minutes. Cell proteins were detected
using the Bio-Rad Protein Assay Dye Reagent (Bio-Rad, Hercules,
CA). All experiments were conducted in triplicate.
To evaluate the effects of protein tyrosine phosphorylation on
COX activity, cells were preincubated with the protein kinase
inhibitor Tyrphostin 47 (300 mM) for 30 min.
Prostaglandin E2 assay
Concentration of PGE2 in the cell incubation medium was
determined by radioimmunoassay, using specific antibodies
according to procedures reported elsewhere (Gobbetti et al.,
1999). The assay sensitivity was 7.5 pg/ml; intra- and inter-assay
coefficients of variations were 8% and 12%, respectively. The
PGE2 concentration was normalized to cell protein.
Cell migration and invasion assays
Cell migration and invasion assays were performed using 24-
well Transwell Boyden chambers (Corning Costar Corporation,
Cambridge, MA).
Cell motility was measured by counting the number of cells
crossing 8-micron pore size polycarbonate membranes coated with
10 mg/ml of fibronectin, and cell invasion was determined by
counting the number of cells invading through a Matrigel-coated
membrane that simulates basement membrane. Cells were
harvested, washed twice with a serum-free medium, and re-
suspended at 80,000 cells/ml. The upper chambers (inserts)
containing uncoated or Matrigel-coated membrane were filled
with 100 ml of cell suspension in DMEM containing 0.1% BSA,
with or without the test substance, while the lower chambers (wells)
were filled with 700 ml of the same cell-free media plus FBS (20%),
that served as a chemo-attractant. Plates were placed in a
humidified CO2 incubator for 24 h at 37uC. The inserts with
membranes were then removed, the upper surface of the
membrane was wiped with cotton swabs to remove non-migrated
cells, and the membranes were fixed and stained with Diff-Quick
staining solution (Dade-Behring Holding GmbH, Liederbach,
Germany). Finally, the stained membranes were quickly washed
with water, inverted and air-dried. Stained cells in three
representative fields were counted at 640 magnification. These
assays were carried out in triplicate.
Wound healing assay
The confluent A17 cell monolayer was wounded by scraping
with a pipette tip, exposed to pharmacological treatments (10 mM
indomethacin) and monitored for wound closure after 18 hours.
Methylation-Specific PCR
DNA methylation patterns in the COX-2/Ptgs2 promoter were
determined by Methylation-Specific PCR (MSP). Briefly, cells
were cultured to subconfluence and harvested to extract genomic
DNA using the QIAamp DNA blood mini kit (Qiagen, Germany).
Genomic DNA was digested with a methylation-sensitive restric-
tion enzyme HpaII, which could cleave a CpG site when it is not
methylated. To ensure that the CpG site was not mutated and
cleavable, the same DNA was digested with a methylation
insensitive restriction enzyme MspI, which could cleave the CpG
site irrespective of the methylation status. In short, when the CpG
site was methylated, amplification of the HpaII digest should have
produced a band similar to the one in the control batch (without
any restriction enzyme). DNA (1 mg) was incubated at 37uC for
24 h in a 100 ml reaction for digestion containing 20 U of MspI,
20 U of HpaII (New England Biolabs Inc., Beverly, MA, USA), or
no enzyme. PCR was carried out using Hot Master Taq DNA
polymerase (5 Prime, Hamburg). Three sets of primers were
designed to amplify the COX-2/PTGS2 promoter sequences
containing one CpG site each: 2569 nt, 2465 nt, and 2186 nt
from the trascription starting site to produce 150, 130, and 170 bp
amplicons, respectively. Primer sequences were: (150 bp) 59-GTC-
CCTGGGAAAGGCGAGTG-39 (sense) and 59-GTTAATTTA-
ATTTCTTCTAT-39 (antisense); (130 bp) 59-CTAATTCCACA-
AGTACAGAT-39 (sense) and 59-CCCCACTGGGGCGCAGT-
CTG-39 (antisense); and (170 bp) 59-AGAGGGCGGTGCAGC-
TCTCT-39 (sense) and 59-CTTTCCGCTTAGGCTTCCCC-39
(antisense). After 2 min. of initial heat denaturing at 94uC, DNA
was amplified by 40 cycles of denaturing at 94uC for 20 sec,
annealing at 62uC for 20 sec and extension at 68uC for 20 s,
followed by 5 min at 68uC.
Treatment with 5-Aza-29-deoxycytidine
BB1 cells were seeded at a density of 1610
5 cells/100 mm-dish
and allowed to attach over 24 h. 5-Aza-29-deoxycytidine (5-Aza-
CdR) (Sigma) was added to the medium, at a final concentration
of 1 or 10 mM and cells were cultured for 72 h. The medium was
replaced every 24 h with a newly prepared medium containing 5-
Aza-CdR. Under demethylated conditions, BB1 cells were
incubated in the absence or presence of PMA 50 ng/ml for 4 h.
Twenty four hours prior to stimulation, the medium was changed
and cells were cultured in DMEM supplemented with 0.5% FBS.
At the end of the treatment period, the genomic DNA was
extracted for MSP analysis and the proteins were extracted for
western analysis.
GENOMICA analysis
Module mapping of comparative gene enrichment was
performed using the Genomica Software, developed by Segal
et al [19] and freely available on the web site: http://genomica.
weizmann.ac.il.
Sources of the datasets and the normalization method are detailed
in the result section for each analysis. In general, we chose the
normalization method we thought to be the most appropriate for
each compendium. Compendia the datasets of which belonged to
the same original study were used as they were downloaded without
any further normalization, except the mean gene centering of the
genes. Compendia obtained by concatenating multipledatasetsfrom
independent studies with different experimental design were
normalized according to RMA-algorithm and then gene mean
centered. Compendia obtained by concatenating multiple datasets
fromindependentstudies,butwithsimilarexperimentaldesign,were
normalized separately before concatenating them, as described by
Segal et al [19]. Briefly, expression values were Log2 transformed
and processed by subtracting the mean value for each gene across all
samples of the compendium from all data points, so that in all cases
expression values of each data point were reported as positive or
negativedepending onwhetherit washigher or lowerthan the mean
value of that gene across the samples.
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value was respectively above or below cut-off values of fold-change
respect to mean value. The cut-off we choose varied from 61.3 to
2.0 depending on the compendium. Statistical analysis of the
enrichment is an implicit function of the GENOMICA algorithm,
which calculates P of the hypothesis that the fraction of over-
expressed or underexpressed genes in particular samples was
consistent with that randomly expected, according to the
hypergeometric distribution. P,0.05 upon False Discovery Rate
(FDR)-correction was accepted as statistically significant.
Cluster analyses
Cluster analyses were performed using Cluster 3.0 software
developed by Eisen et al. [34]. All analyses were carried out on
normalized and log2 transformed dataset values. Uncentered
Pearson-correlation was used as the similarity metrics and average
linkage as the clustering method.
Supporting Information
Table S1 Signal transduction-related microarray.
Found at: doi:10.1371/journal.pone.0014131.s001 (0.16 MB
PDF)
Table S2 Correlation indexes for the signal transduction-related
gene profiles.
Found at: doi:10.1371/journal.pone.0014131.s002 (0.04 MB
PDF)
Table S3 Reference source of publicly available human
microarray datasets.
Found at: doi:10.1371/journal.pone.0014131.s003 (0.08 MB
PDF)
Table S4 Percentage fraction of samples overexpressing Ptgs2.
Found at: doi:10.1371/journal.pone.0014131.s004 (0.05 MB
PDF)
Table S5 A17 signatures.
Found at: doi:10.1371/journal.pone.0014131.s005 (0.26 MB
PDF)
Table S6 Reference source of microarray dataset of samples
undergone hormonal therapy.
Found at: doi:10.1371/journal.pone.0014131.s006 (0.05 MB
PDF)
Figure S1 DNA Methylation pattern in the COX-2/PTGS2
promoter were determined by Methylation-Specific PCR (MSP).
Treatment with IL-1b, HGF and TGFb for 2, 4 and 6 hours, was
not able to induce the COX-2 expression in BB1, while resulted in
increased levels of COX2 in the A17 cell (a). Three primers were
designed for amplifying the sequence containing three side CpG in
the promoter of COX2: 2465 nt (A), 2569 nt (B) and 2186 nt
(C) (b and c). COX2 promoter resulted hypermethylated in BB1
cells, but it was demethylated in A17 cells (d). The state of
demethylation of the promoter COX2 was examined by MSP
after treatment of cells BB1 for 72 hours with the substance
demethylating 5-aza-CdR at a concentration of 1 and 10 mM (e).
Found at: doi:10.1371/journal.pone.0014131.s007 (1.70 MB TIF)
Figure S2 Preliminary unsupervised cluster analysis of the most
differentially expressed genes (SD.1.8), restricted to breast
cancers only, confirmed that the dataset previously described in
figure 3 comprises all five subtypes, including the basal-like one
(ER-negative, HER-2-negative, KRT5-positive) (yellow square).
Found at: doi:10.1371/journal.pone.0014131.s008 (8.20 MB TIF)
Figure S3 When breast tumors were clusterized together with
mesenchymal samples (breast stroma, MSCs, sarcomas), basal-like
samples clusterized with breast cancers, whereas breast stroma,
MSCs and sarcomas formed distinct clusters (a). Thus, we
supervised whole-genome clusters searching for any gene cluster
that might relate basal-like to epithelial or mesenchymal samples.
We identified three gene sets with an apparently interesting
pattern of expression, and performed hierarchical clusterization of
these genes separately (b). Cluster 1 comprised apparently peculiar
genes of basal-like cells and normal breast/organelle samples. As
expected, it included KRT5, KRT14 and KRT15. Hierarchical
clusterization of these genes did not clearly separate epithelial and
mesenchymal phenotypes, thus indicating that these genes failed to
directly relate basal-like cells to non-basal breast cancer or
mesenchymal phenotypes. Cluster 2 relates basal-like samples to
non-basal breast cancers and breast stroma, whereas MSCs and
Sarcomas formed distinct clusters. In Cluster 3, most of the basal-
like samples fell into a large cluster which included all
mesenchymal samples, along with a limited number of non-basal
breast cancers. Finally we clusterized breast cancers and
mesenchymal samples for the genes comprised in the stemness-,
angiogenesis- and signal transduction-related arrays described
above, both considering all the genes of the array or restricting
analysis to those over-expressed by A17 cells (A17-signatures) (c).
In all cases, basal-like samples clusterized more closely to breast
than mesenchymal samples.
Found at: doi:10.1371/journal.pone.0014131.s009 (9.18 MB TIF)
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